4 New HIV specific latency reversing agents with novel targets that synergise with HIV Tat and the bromodomain inhibitor, JQ1 to reactivate HIV from primary cells.

by J. Jacobson, B. Sleebs, K. Jarman, W. Nguyen, T. Mota, L. Harty, G. Khoury, N. Tay, P. Cameron, S. Lewin, D.F.J. Purcell
Published 2017-07-01

Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques

by Z. Li, M. Khanna, S. L. Grimley, P. Ellenberg, C. A. Gonelli, Wen Shi Lee, T. H. Amarasena, A. D. Kelleher, D. F. J. Purcell, S. J. Kent, C. Ranasinghe
Published 2020-12-01

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal

by T.M. Mota, G. Khoury, J.C. Jacobson, H.K. Lu, F. Wightman, d.e.r. Sluis, J.L. Anderson, P.U. Cameron, S.R. Lewin, D.F.J. Purcell, R.M. Van
Published 2016-07-01